


PRODUCT INFORMATION



Atuveciclib

Item No. 44337

CAS Registry No.: 1414943-94-4
Formal Name: (+)-4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine
Synonym: BAY-1143572
MF: C₁₈H₁₈FN₅O₂S
FW: 387.4
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Atuveciclib is supplied as a solid. A stock solution may be made by dissolving the atuveciclib in the solvent of choice, which should be purged with an inert gas. Atuveciclib is soluble (≥10 mg/ml) in DMSO.

Description

Atuveciclib is an inhibitor of Cdk9/cyclin T1 (IC₅₀ = 6 nM).¹ It is selective for Cdk9/cyclin T1 over Cdk1/cyclin B, Cdk2/cyclin E, Cdk3/cyclin E, Cdk5/p35, Cdk6/cyclin D3, and Cdk7/cyclin H/Mat1 (IC₅₀s = 1,100, 1,000, 890, 1,600, >10,000 and >10,000 nM, respectively). *In vivo*, atuveciclib (6.25 and 12.5 mg/kg) reduces tumor area in a MOLM-13 acute myeloid leukemia (AML) mouse xenograft model. It reduces skin thickness and scaling in a mouse model of psoriasis induced by imiquimod (Item No. 14956).²

References

1. Lücking, U., Scholz, A., Lienau, P., *et al.* Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer. *ChemMedChem* **12**(21), 1776-1793 (2017).
2. Zhao, F., Wang, Y., Zuo, H., *et al.* Cyclin-dependent kinase 9 (CDK9) inhibitor atuveciclib ameliorates imiquimod-induced psoriasis-Like dermatitis in mice by inhibiting various inflammation factors via STAT3 signaling pathway. *Int. Immunopharmacol.* **129**, 111652 (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/22/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM